The U.S. FDA should audit the hiring practices of its Bioresearch Monitoring (BIMO) program to see whether efforts to attract more investigators and boost drug trial oversight are paying off, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback